Trevena, Inc. (NASDAQ:TRVN – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.24 and traded as low as $1.30. Trevena shares last traded at $1.30, with a volume of 667 shares trading hands.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on Trevena in a research note on Wednesday. They issued a “sell” rating for the company.
View Our Latest Stock Report on TRVN
Trevena Trading Down 4.4 %
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading
- Five stocks we like better than Trevena
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Must-Own Stocks to Build Wealth This Decade
- How to Most Effectively Use the MarketBeat Earnings Screener
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.